Mid-term outcome of intravitreal bevacizumab for branch retinal vein occlusion with macular edema

To report the outcome of intravitreal injection of bevacizumab for branch retinal vein occlusion (BRVO) with macular edema. Cases and Method : This study was made on 33 eyes of 33 patients who received intravitreal bevacizumab for BRVO with macular edema. The age ranged from 44 to 78 years, average 63 years. Cases were followed up for 8 to 49 months, average 15 months, after treatment. Visual acuity was evaluated in terms of logMAR. Results : Visual acuity averaged 0.47 before treatment and 0.23 at the last visit. The difference was significant (p<0.001). Central retinal thickness, as measured by optical cohererence tomography (OCT), averaged 552.7μm before treatment and 336.8 μm at the final visit. The difference was significant (p<0.001). Conclusion : While macular edema secondary to BRVO may spontaneously resolve, intravitreal bevacizumab may result in maintaining fair visual acuity when applied during the early stage after onset.